At 12-month follow-up, BW dropped from 79 to 73 kg while maintaining excellent glycemic control (HbA1c 40 mmol/mol)
Landmark studies such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown significant reductions in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
Zhou Y, Zhou X, Song Y, Tian Q, Li S, Li T, et al
However: They are not first-line treatments for acute emergencies
Their programs are grounded in holistic weight-loss principles, integrating diet, exercise, wellness, and pharmacotherapy under medical supervision
Finally, GSH showed a relationship with GABA that was region, age and state dependent